Top

Published in:

01-09-2011 | Original Article

Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus

Authors: Yi-Ning Chen, Ching Ching Wu, Tsang Long Lin

Published in: Archives of Virology | Issue 9/2011

Abstract

Little is known about the neutralizing epitopes in turkey coronavirus (TCoV). The spike (S) protein gene of TCoV was divided into 10 fragments to identify the antigenic region containing neutralizing epitopes. The expression and antigenicity of S fragments was confirmed by immunofluorescence antibody (IFA) assay using an anti-histidine monoclonal antibody or anti-TCoV serum. Polyclonal antibodies raised against expressed S1 (amino acid position 1 to 573 from start codon of S protein), 4F/4R (482-678), 6F/6R (830-1071), or Mod4F/Epi4R (476-520) S fragment recognized native S1 protein and TCoV in the intestines of TCoV-infected turkey embryos. Anti-TCoV serum reacted with recombinant 4F/4R, 6F/6R, and Mod4F/Epi4R in a western blot. The results of a virus neutralization assay indicated that the carboxyl terminal region of the S1 protein (Mod4F/Epi4R) or the combined carboxyl terminal S1 and amino terminal S2 protein (4F/4R) possesses the neutralizing epitopes, while the S2 fragment (6F/6R) contains antigenic epitopes but not neutralizing epitopes.

Guy JS (2003) Turkey Coronavirus Enteritis. In: Saif YM, Barnes HJ, Glisson JR, Fadly AM, McDougald LR, Swayne DE (eds) Disease of poultry, 11th edn. Iowa State University Press, Ames, pp 300–307

Lin TL, Loa CC, Wu CC, Bryan T, Hooper T, Schrader D (2002) Antigenic relationship of turkey coronavirus isolates from different geographic locations in the United States. Avian Dis 46:466–472PubMedCrossRef

Dea S, Marsolais G, Beaubien J, Ruppanner R (1986) Coronaviruses associated with outbreaks of transmissible enteritis of turkeys in Quebec: hemagglutination properties and cell cultivation. Avian Dis 30:319–326PubMedCrossRef

Gomaa MH, Yoo D, Ojkic D, Barta JR (2008) Seroprevalence of turkey coronavirus in North American turkeys determined by a newly developed enzyme-linked immunosorbent assay based on recombinant antigen. Clin Vaccine Immunol 15:1839–1844PubMedCrossRef

Cavanagh D, Mawditt K, Sharma M, Drury SE, Ainsworth HL, Britton P, Gough RE (2001) Detection of a coronavirus from turkey poults in Europe genetically related to infectious bronchitis virus of chickens. Avian Pathol 30:355–368PubMedCrossRef

Teixeira MC, Luvizotto MC, Ferrari HF, Mendes AR, da Silva SE, Cardoso TC (2007) Detection of turkey coronavirus in commercial turkey poults in Brazil. Avian Pathol 36:29–33PubMedCrossRef

Gomaa MH, Yoo D, Ojkic D, Barta JR (2009) Virus shedding and serum antibody responses during experimental turkey coronavirus infections in young turkey poults. Avian Pathol 38:181–186PubMedCrossRef

Loa CC, Lin TL, Wu CC, Bryan T, Thacker HL, Hooper T, Schrader D (2001) Humoral and cellular immune responses in turkey poults infected with turkey coronavirus. Poult Sci 80:1416–1424PubMed

http://www.ictvonline.org/virusTaxonomy.asp?version=2009. Accessed 29 March 2011

10.

Woo PC, Lau SK, Huang Y, Yuen KY (2009) Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med 234:1117–1127CrossRef

11.

Lin TL, Loa CC, Tsai SC, Wu CC, Bryan TA, Thacker HL, Hooper T, Schrader D (2002) Characterization of turkey coronavirus from turkey poults with acute enteritis. Vet Microbiol 84:179–186PubMedCrossRef

12.

Ignjatovic J, Galli L (1994) The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccine chickens. Arch Virol 138:117–134PubMedCrossRef

13.

Taguchi F, Kubo H (1995) Localization of neutralizing epitopes and receptor-binding site in murine coronavirus spike protein. Adv Exp Med Biol 380:359–365PubMed

14.

Daniel C, Talbot PJ (1990) Protection of mice from lethal coronavirus MHV-A59 infection by monoclonal affinity-purified spike glycoprotein. Adv Exp Med Bio 276:205–210

15.

Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S (2009) Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli elicits potent neutralizing antibody and protective immunity. Virology 393:144–150PubMedCrossRef

16.

Ishi K, Hasegawa H, Nagata N, Ami Y, Fukushi S, Taguchi F, Tsunetsugu-Yokota Y (2009) Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. Microbiol Immunol 53:75–82CrossRef

17.

Johnson MA, Pooley C, Ignjatovic J, Tyack SG (2003) A recombinant fowl adenovirus expression the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. Vaccine 21:2730–2736PubMedCrossRef

18.

Delmas B, Laude H (1990) Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol 64:5367–5375PubMed

19.

Spiga O, Bernini A, Ciutti A, Chiellini S, Menciassi N, Finetti F, Causarono V, Anselmi F, Prischi F, Niccolai N (2003) Molecular modeling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. BBRC 310:78–83PubMed

20.

Godet M, Grosclaude J, Delmas B, Laude H (1994) Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J Virol 68:8008–8016PubMed

21.

Tresnan DB, Holmes KV (1998) Feline aminopeptidase N is a receptor for all group I coronaviruses. Adv Exp Med Biol 440:69–75PubMedCrossRef

22.

Ohtsuka N, Taguchi F (1997) Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. J Virol 71:8860–8863PubMed

23.

Zhao J, Wang W, Yuan Z, Jia R, Zhao Z, Xu X, Lv P, Zhang Y, Jiang C, Gao XM (2007) A study on antigenicity and receptor-binding ability of fragment 450–650 of the spike protein of SARS coronavirus. Virology 359:362–370PubMedCrossRef

24.

Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77:8801–8811PubMedCrossRef

25.

Madu IG, Roth SL, Belouzard S, Whittaker GR (2009) Characterization of highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J Virol 83:7411–7421PubMedCrossRef

26.

He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S (2004) Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 173:4050–4057PubMed

27.

Hu H, Li L, Kao RY et al (2005) Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthesized overlapping peptide library. J Comb Chem 7:648–656PubMedCrossRef

28.

Zhou T, Wang H (2004) An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 78:7217–7226PubMedCrossRef

29.

Ignjatovic J, Sapats S (2005) Identification of previously unknown antigenic epitopes on S and N proteins of avian infectious bronchitis virus. Arch Virol 150:1813–1831PubMedCrossRef

30.

Kubo H, Yamada YK, Taguchi F (1994) Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J Virol 68:5403–5410PubMed

31.

Moore KM, Jackwood MW, Hilt DA (1997) Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus. Arch Virol 142:2249–2256PubMedCrossRef

32.

Yoo D, Deregt D (2001) A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization. Clin Diagn Lab Immunol 8:297–302PubMed

33.

Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan TH, Chou CF, Loh CB, Wang S, Fu J, Yang X, Lim SG, Hong W, Tan YJ (2005) Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 79:3289–3296PubMedCrossRef

34.

Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G, Wang W, Yin X, Zhao Y, Qu X, Ding M, Deng H (2004) Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 78:6938–6945PubMedCrossRef

35.

Sun D, Feng L, Shi H, Chen J, Cui X, Chen H, Liu S, Tong Y, Wang Y, Tong G (2008) Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein. Vet Microbiol 131:73–81PubMedCrossRef

36.

Yu MW, Scott JK, Fournier A, Talbot PJ (2000) Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides. Virology 271:182–196PubMedCrossRef

37.

Zhong L, Haynes L, Struble EB, Tamin A, Virata-Theimer ML, Zhang P (2009) Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Biochem Biophys Res Commun 390:1056–1060PubMedCrossRef

38.

Kida K, Hohdatsu T, Fuji K, Koyama H (1999) Selection of antigenic variants of the S glycoprotein of feline infectious peritonitis virus and analysis of antigenic sites involved in neutralization. J Vet Med Sci 61:935–938PubMedCrossRef

39.

Mituki YY, Ohnishi K, Takgi H, Oshima M, Yamamoto T, Mizukoshi F, Terahara K, Kobayashi K, Yamamoto N, Yamaoka S, Tsunetsugu-Yokota Y (2008) A single amino acid substitution in the S1 and S2spike protein domains determines the neutralization escape phenotype of SARS-CoV. Microbes Infect 10:908–915CrossRef

40.

Niesters HG, Bleumink-Pluym NM, Osterhaus AD, Horzinek MC, van der Zeijst BA (1987) Epitopes on the peplomer protein of infectious bronchitis virus strain M41 as defined by monoclonal antibodies. Virology 161:511–519PubMedCrossRef

41.

Lu L, Manopo I, Leung BP, Chng HH, Ling AE, Chee LL, Ooi EE, Chan S-W, Kwang J (2004) Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 42:1570–1576PubMedCrossRef

42.

Chen H, Schifferli DM (2003) Construction, characterization, and immunogenicity of an attenuated Salmonella enterica serovar typhimurium pgtE vaccine expressing fimbriae with integrated viral epitopes from the spiC promoter. Infect Immun 71:4664–4673PubMedCrossRef

43.

Callebaut P, Enjuanes L, Pensaert M (1996) An adenovirus recombinant expressing fimbriae with integrated viral epitopes from the spic promoter. Infect Immun 71:309–313

44.

Wesseling JG, Godeke GJ, Schijns VE, Prevec L, Graham FL, Horzinek MC, Rottier PJ (1993) Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J Gen Virol 74:2061–2069PubMedCrossRef

45.

Zakhartchouk AN, Viswanathan S, Mahony JB, Gauldie J, Babiuk LA (2005) Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol 86:211–215PubMedCrossRef

46.

Hebben M, Duguesne V, Cronier J, Rossi B, Aubert A (2004) Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy. J Feline Med Surg 6:111–118PubMedCrossRef

47.

Wang X, Schnitzlein WM, Tripathy DN, Girshick T, Khan MI (2002) Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. Avian Dis 46:831–838PubMedCrossRef

48.

Breslin JJ, Smith LG, Guy JS (2001) Baculovirus expression of turkey coronavirus nucleocapsid protein. Avian Dis 45:136–143PubMedCrossRef

49.

Guy JS, Barnes HJ, Smith LG, Breslin J (1997) Antigenic characterization of a turkey coronavirus identified in poult enteritis- and mortality syndrome-affected turkeys. Avian Dis 41:583–590PubMedCrossRef

50.

Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276:172–174PubMedCrossRef

51.

Rice P, Longden I, Bleasby A (2000) EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16:276–277PubMedCrossRef

52.

Loa CC, Wu CC, Lin TL (2006) Comparison of 3′-end encoding regions of turkey coronavirus isolates from Indiana, North Carolina, and Minnesota with chicken infectious bronchitis coronavirus strains. Intervirology 49:230–238PubMedCrossRef

53.

Jackwood MW, Boynton TO, Hilt DA, McKinley ET, Kissinger JC, Paterson AH, Robertson J, Lemke C, McCall AW, Williams SM, Jackwood JW, Byrd LA (2009) Emergence of a group 3 coronavirus through recombination. Virology 398:98–108CrossRef

54.

Lenstra JA, Kusters JG, Koch G, van der Zeijst BAM (1989) Antigenicity of the peplomer protein of infectious bronchitis virus. Mol Immunol 25:7–15CrossRef

55.

Tan B, Wang H, Shang L, Yang T (2009) Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection. Arch Virol 154:1117–1124PubMedCrossRef

56.

Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561–564PubMedCrossRef

57.

Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JKH, Wong L, He W, Ma C, Chan K, Ho DD, Yuen K (2005) SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23:4959–4968PubMedCrossRef

58.

Laddy DJ, Weiner DB (2006) From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 25:99–123PubMedCrossRef

59.

Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ (2008) Molecular and cellular mechanisms of DNA vaccines. Hum Vaccines 4:453–456CrossRef

Title: Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus
Authors: Yi-Ning Chen
Ching Ching Wu
Tsang Long Lin
Publication date: 01-09-2011
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 9/2011
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-011-1020-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2011

Design and evaluation of a recombinant multi-epitope-based ELISA for the serological surveillance of HEV infection in northern China

Immunization with dendritic cells transfected in vivo with HIV-1 plasmid DNA induces HIV-1-specific immune responses

Development time of IgG antibodies to West Nile virus

Detection and follow-up of torque teno midi virus (“small anelloviruses”) in nasopharyngeal aspirates and three other human body fluids in children

The complete nucleotide sequence and genome organization of a novel carmovirus - honeysuckle ringspot virus isolated from honeysuckle

Molecular epidemiology of norovirus gastroenteritis in children in Jiangmen, China, 2005–2007

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page